After the radiolabeled somatostatin peptide analogues have being used successfully in neuroendocrine tumors for nuclear imaging and therapy (30, 31), GRPR radioprotections (GRPR radiolagind5,6) have been synthesized and used in preclinical and clinical studies, currently including the prostate (32, 33). Here, SST is linked to neuroendocrine neoplasm.